• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abiomed touts survival benefits in Impella 2.5 cardiogenic shock PCI treatment study

Abiomed touts survival benefits in Impella 2.5 cardiogenic shock PCI treatment study

July 3, 2017 By Fink Densford

Abiomed

Abiomed (NSDQ:ABMD) today released results from a study of its Impella 2.5 heart pump examining the use of the device in patients with acute myocardial infarction complicated by cardiogenic shock, touting survival benefits associated with the device.

Results from the Danvers, Mass.-based company’s study were published in the Journal of Interventional Cardiology.

Data from the 36-patient retrospective study came from real-world outcomes with the Impella 2.5 during percutaneous coronary interventions on unprotected left main coronary arteries, Abiomed said. The study aimed to analyze whether the initiation of hemodynamic support before PCI would improve survival compared to support post-PCI.

Results indicated that patients treated with the Impella pre-PCI had survival rates of 55% at discharge and 48% at 30-days post discharge, versus 19% and 13% respectively for those treated post-PCI, Abiomed said.

“Patients with cardiogenic shock complicating an acute myocardial infarction due to an unprotected left main coronary artery culprit lesion are some of the sickest and most clinically challenging patients admitted in the cath lab. Our data suggests that early placement of Impella before PCI is vital to survival,” study 1st author Dr. Perwaiz Meraj of Northwell Health said in a press release.

Abiomed said the data supports prior data showing percutaneous heart pumps improved survival in cardiogenic shock patients.

“We commend Dr. Meraj and his coauthors on this application of real-world evidence. We are pleased that this adds to the body of research showing the benefit of placing Impella early and before PCI in the setting of cardiogenic shock,” chief medical officer Dr. Seth Bilazarian said in a prepared statement.

In May, Abiomed said it launched a 3rd generation Impella CP heart pump, touting new features and improved performance with the new model.

Filed Under: Cardiovascular, Clinical Trials Tagged With: Abiomed

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy